Barlesi F, Mazieres J, Merlio JP, Debieuvre D, Mosser J, Lena H, et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet. 2016;387:1415–26.

Article  CAS  PubMed  Google Scholar 

Jordan EJ, Kim HR, Arcila ME, Barron D, Chakravarty D, Gao J, et al. Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies. Cancer Discov. 2017;7:596–609.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561–6.

Article  CAS  PubMed  Google Scholar 

Qi R, Yu Y, Shen M, Lev D, He S. Current status and challenges of immunotherapy in ALK rearranged NSCLC. Front Oncol. 2022;12: 1016869.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shaw AT, Solomon B. Targeting anaplastic lymphoma kinase in lung cancer. Clin Cancer Res. 2011;17:2081–6.

Article  CAS  PubMed  Google Scholar 

Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368:2385–94.

Article  CAS  PubMed  Google Scholar 

Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371:2167–77.

Article  PubMed  Google Scholar 

Solomon BJ, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, et al. Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in ALK-mutation-positive non–small-cell lung cancer. J Clin Oncol. 2018;36:2251–8.

Article  CAS  PubMed  Google Scholar 

Dagogo-Jack I, Shaw AT. Crizotinib resistance: implications for therapeutic strategies. Ann Oncol. 2016;27:iii42–50.

Article  PubMed  PubMed Central  Google Scholar 

Shaw AT, Kim TM, Crinò L, Gridelli C, Kiura K, Liu G, et al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2017;18:874–86.

Article  CAS  PubMed  Google Scholar 

Novello S, Mazières J, Oh IJ, de Castro J, Migliorino MR, Helland Å, et al. Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study. Ann Oncol. 2018;29:1409–16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim ES, Barlesi F, Mok T, Ahn MJ, Shen J, Zhang P, et al. ALTA-2: phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib. Future Oncol. 2021;17:1709–19.

Article  CAS  PubMed  Google Scholar 

Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018;19:1654–67.

Article  CAS  PubMed  Google Scholar 

Mok T, Camidge DR, Gadgeel SM, Rosell R, Dziadziuszko R, Kim DW, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol. 2020;31:1056–64.

Article  CAS  PubMed  Google Scholar 

Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, et al. Brigatinib versus crizotinib in ALK inhibitor-naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial. J Thorac Oncol. 2021;16:2091–108.

Article  CAS  PubMed  Google Scholar 

Chiari R, Metro G, Iacono D, Bellezza G, Rebonato A, Dubini A, et al. Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: results of a multicenter analysis. Lung Cancer. 2015;90:255–60.

Article  PubMed  Google Scholar 

Recondo G, Facchinetti F, Olaussen KA, Besse B, Friboulet L. Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI? Nat Rev Clin Oncol. 2018;15:694–708.

Article  CAS  PubMed  Google Scholar 

Kosaka T, Yajima T, Yamaki E, Nakazawa S, Tomizawa K, Onozato R, et al. Long-term complete response in a patient with postoperative recurrent ALK-rearranged lung adenocarcinoma treated with crizotinib: a case report. Mol Clin Oncol. 2019;11:309–12.

PubMed  PubMed Central  Google Scholar 

Rangachari D, Le X, Shea M, Huberman MS, VanderLaan PA, Kobayashi SS, et al. Cases of ALK-rearranged lung cancer with 5-year progression-free survival with crizotinib as initial precision therapy. J Thorac Oncol. 2017;12:e175–7.

Article  PubMed  PubMed Central  Google Scholar 

Van Damme E, Kiselinova M, Van Schoote E. Complete remission for 4 years with crizotinib in advanced ALK-positive non-small cell lung cancer after thoracostomy for empyema. Tumori. 2019;105:NP35–7.

Article  PubMed  Google Scholar 

Li Y, Zhang T, Zhang J, Li W, Yuan P, Xing P, et al. Response to crizotinib in advanced ALK-rearranged non-small cell lung cancers with different ALK-fusion variants. Lung Cancer. 2018;118:128–33.

Article  PubMed  Google Scholar 

Yoshida T, Oya Y, Tanaka K, Shimizu J, Horio Y, Kuroda H, et al. Differential crizotinib response duration among ALK fusion variants in ALK-positive non-small-cell lung cancer. J Clin Oncol. 2016;34:3383–9.

Article  CAS  PubMed  Google Scholar 

Kron A, Alidousty C, Scheffler M, Merkelbach-Bruse S, Seidel D, Riedel R, et al. Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer. Ann Oncol. 2018;29:2068–75.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang G, Ma D, Xu H, Yang L, Li J, Xing P, et al. Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK-positive non-small cell lung cancer: a retrospective, real-world study. Cancer Med. 2019;8:5823–30.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aguado de la Rosa C, Cruz Castellanos P, Lázaro-Quintela M, Dómine M, Vázquez Estévez S, López-Vivanco G, et al. Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study). Lung Cancer. 2022;173:83–93.

Article  CAS  PubMed  Google Scholar 

Duruisseaux M, Besse B, Cadranel J, Pérol M, Mennecier B, Bigay-Game L, et al. Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study. Oncotarget. 2017;8:21903–17.

Article  PubMed  PubMed Central  Google Scholar 

Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 2011;12:1004–12.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Emirzeoglu L, Olmez O. ALK-positive locally advanced lung cancer in a patient who achieved long-term complete response with crizotinib: a case report. Exp Ther Med. 2022;24:1–5.

Article  Google Scholar 

Sacher AG, Dahlberg SE, Heng J, Mach S, Jänne PA, Oxnard GR. Association between younger age and targetable genomic alterations and prognosis in non-small-cell lung cancer. JAMA Oncol. 2016;2:313–20.

Article  PubMed  PubMed Central  Google Scholar 

Singal G, Miller PG, Agarwala V, Li G, Kaushik G, Backenroth D, et al. Association of patient characteristics and tumor genomics with clinical outcomes among patients with non–small cell lung cancer using a clinicogenomic database. JAMA. 2019;321:1391–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27:4247–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wong DWS, Leung ELH, So KKT, Tam IYS, Sihoe ADL, Cheng LC, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer. 2009;115:1723–33.

Article  CAS  PubMed  Google Scholar 

Doebele RC, Lu X, Sumey C, Maxson DA, Weickhardt AJ, Oton AB, et al. Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer. Cancer. 2012;118:4502–11.

Article  CAS  PubMed  Google Scholar 

Fallet V, Cadranel J, Doubre H, Toper C, Monnet I, Chinet T, et al. Prospective screening for ALK: clinical features and outcome according to ALK status. Eur J Cancer. 2014;50:1239–46.

Article  CAS  PubMed